Posted by Michael Wonder on 09 Jan 2019
New drug to halve heart patients' cholesterol levels
9 January 2019 - A second drug has been approved for use in Australia for patients with high cholesterol who are difficult to treat and are at high risk of heart disease.
Praluent (alirocumab) is part of a new class of medicines that target a protein called PCSK9 in the liver.
A submission has been made to the Pharmaceutical Benefits Advisory Committee to have the drug subsidised for patients with a genetic disorder that causes dangerously high cholesterol levels and for patients who have a history of acute coronary syndrome and diabetes.
